Gastroenterology

Top Story

Researchers question quality of data supporting low FODMAP diet in IBS

April 27, 2017

Randomized controlled trials of the low FODMAP diet for irritable bowel syndrome carry a high risk for bias and have insufficient follow-up, and the improvements in symptoms observed in these trials could be driven by a placebo response, according to new research published in Alimentary Pharmacology and Therapeutics.

“This relatively new diet has gained much attention, and information about the diet is available on the internet in excess,” Laura Rindom Krogsgaard, MD, of the department of gastroenterology at Zealand University Hospital in Denmark, and colleagues wrote. “Experts recommend the diet as a first-line treatment for IBS and refer to the diet as being supported by a high level of evidence,” but the quality of available evidence has not yet been evaluated, they added.

In the Journals Plus

CDI more prevalent in allogeneic stem cell recipients

April 27, 2017
Clostridium difficile infection was more prevalent in patients undergoing allogeneic stem cell transplantation compared with patients undergoing autologous stem cell
Meeting News

EASL releases Clinical Practice Guideline for the management of HBV

April 27, 2017
AMSTERDAM — The European Association for the Study of the Liver presented five new clinical practice guidelines for the diagnosis and management of various liver…
In the Journals

High-quality diet linked to lower CRC risk across racial, ethnic groups

April 26, 2017
Researchers associated high-quality dietary patterns defined by four different diet quality indexes with a reduced risk for colorectal cancer across a number of racial…
In the Journals

Half of diverticulitis patients diagnosed in ER can avoid hospital admission

April 26, 2017
Patients diagnosed with uncomplicated diverticulitis in the emergency department who were discharged home with a prescription for oral antibiotics had a very low risk…
More News Headlines »
CME

Rapid Response from Barcelona: New Data in HCV Treatment

This activity is supported by an educational grant from AbbVie and Merck & Co., Inc.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
GI Bookshelf

Chapter 5: The Malabsorption Syndrome

From Clinical Nutrition in Gastrointestinal Disease
More »
Featured
International Liver Congress

International Liver Congress

Video
Meeting News

VIDEO: Physician discusses future of HBV treatment, path to cure

April 20, 2017
More »
Advertisement
Advertisement